Floatz logo

Metformin

Esophageal Adenocarcinoma

Dan ZandbergSmall moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

47 Active assets in the Esophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
I-Mab Biopharma US Limited
Phase 3BB
Cetuximab
BeOne Medicines
Phase 2B
Capecitabine
I-Mab Biopharma US Limited
Phase 3B
Tislelizumab
BeOne Medicines
Phase 3B
Durvalumab
University of California, Irvine
Phase 2B

View all 50 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →